Advertisement

Clinical and Experimental Medicine

, Volume 12, Issue 2, pp 127–132 | Cite as

Significance of persistence of antibodies against Leishmania infantum in sicilian patients affected by acute visceral leishmaniasis

  • Pasquale MansuetoEmail author
  • Ilenia Pepe
  • Aurelio Seidita
  • Francesca Scozzari
  • Giustina Vitale
  • Francesco Arcoleo
  • Inglese Elvira
  • Enrico Cillari
  • Giovam Battista Rini
  • Nicola Napoli
  • Salvatore Di Rosa
  • Serafino Mansueto
  • Gaetana Di Fede
Short Communication

Abstract

The background of this article is as follows: Few data are available about the persistence of serum-specific IgG antibodies to L. infantum after acute VL. The objective of this article is to evaluate the persistence of antibodies against L. infantum in patients healed from acute VL, and the kinetic of the same antibodies observed in 2 cases of VL relapse and 2 cases of resistance to therapy. The methods which we used to obtain our objective are the following: 55 apparently immunocompetent, HIV-negative patients were examined for antibodies to L. infantum by IFAT over 14 years period, and we got the following results: Serum-specific IgG antibodies titers decrease slowly, but constantly. In the patients with a diagnosis of VL relapse, the kinetic of antibodies was characterized by an initial reduction, and a subsequent antibody levels rapidly increase, while in the patients with a clinical and parasitological diagnosis of VL not responding to specific therapy, we demonstrated persistent high level of antibodies to L. infantum. Finally, we conclude that specific antibodies to L. infantum might persist for many years, and decrease slowly, but steadily. The persistence of these specific antibodies is not related to poor therapeutic response or prognosis, but an acute increase in their levels might be a sentinel of a VL relapse, while persistence of high antibody levels could suggest a resistance to therapy.

Keywords

Visceral leishmaniasis L. infantum Kinetic of antibodies Persistence of antibodies VL relapse VL resistance 

Abbreviations

VL

Visceral leishmaniasis

IFAT

Immunofluorescent antibody test

Notes

Acknowledgments

This study was supported by grants from MIUR (Italian University and Research Ministry), former 60% funds, to Pasquale Mansueto. No support was received from the pharmaceutical and diagnostic industry.

Conflict of interest

The authors declare they have no conflict of interest.

References

  1. 1.
    Dujardin JC, Campino L, Cañavate C, Dedet JP, Gradoni L, Soteriadou K, Mazeris A, Ozbel Y, Boelaert M (2008) Spread of vector-borne diseases and neglect of Leishmaniasis. Europe Emerg Infect Dis 14(7):1013–1018CrossRefGoogle Scholar
  2. 2.
  3. 3.
    Chappuis F, Sundar S, Hailu A, Ghalib H, Rijal S, Peeling RW, Alvar J, Boelaert M (2007) Visceral leishmaniasis: what are the needs for diagnosis, treatment and control? Nat Rev Microbiol 5(11):873–882PubMedCrossRefGoogle Scholar
  4. 4.
    Mansueto P, Vitale G, Di Lorenzo G, Rini GB, Mansueto S, Cillari E (2007) Immunopathology of leishmaniasis: an update. Int J Immunopathol Pharmacol 20(3):435–445PubMedGoogle Scholar
  5. 5.
    Anam K, Afrin F, Banerjee D, Pramanik N, Guha SK, Goswami RP, Gupta PN, Saha SK, Ali N (1999) Immunoglobulin subclass distribution and diagnostic value of Leishmania donovani antigen-specific immunoglobulin G3 in Indian kala-azar patients. Clin Diagn Lab Immunol 6:231–235PubMedGoogle Scholar
  6. 6.
    Da Matta VL, Hoshino-Shimizu S, Dietze R, Corbett CE (2000) Detection of specific antibody isotypes and subtypes before and after treatment of American visceral leishmaniasis. J Clin Lab Anal 14:5–12PubMedCrossRefGoogle Scholar
  7. 7.
    Cascio G (1970) Behavior of antibodies (titrated by means of the immunofluorescence test) in visceral leishmaniasis treated by antimony therapy. Pediatria 78(3):497–504PubMedGoogle Scholar
  8. 8.
    Avila JL, Rojas M, García L (1998) Persistence of elevated levels of galactosyl-alpha(1–3)galactose antibodies in sera from patients cured of visceral leishmaniasis. J Clin Microbiol 26(9):1842–1847Google Scholar
  9. 9.
    De Almeida Silva L, Romero HD, Prata A, Costa RT, Nascimento E, Carvalho SF, Rodrigues V (2006) Immunologic tests in patients after clinical cure of visceral leishmaniasis. Am J Trop Med Hyg 75(4):739–743PubMedGoogle Scholar
  10. 10.
    Hailu A (1990) Pre- and post-treatment antibody levels in visceral leishmaniasis. Trans R Soc Trop Med Hyg 84(5):673–675PubMedCrossRefGoogle Scholar
  11. 11.
    Londner MV, Feinsod FM, Faris R, Rosen G, el Said S, Saah AJ (1988) Persistence of human leishmanial antibodies in an endemic area of visceral leishmaniasis in El Agamy, Egypt. Eur J Epidemiol 4(4):473–476PubMedCrossRefGoogle Scholar
  12. 12.
    Musa AM, Khalil EA, Raheem MA, Zijlstra EE, Ibrahim ME, Elhassan IM, Mukhtar MM, El Hassan AM (2002) The natural history of Sudanese post-kala-azar dermal leishmaniasis: clinical, immunological and prognostic features. Ann Trop Med Parasitol 96(8):765–772PubMedCrossRefGoogle Scholar
  13. 13.
    Mokrani T, Belazzoug S, Bouzid Z, Keddari M (1988) Development of antibodies in children treated for visceral leishmaniasis. Arch Inst Pasteur Alger 56:101–107PubMedGoogle Scholar
  14. 14.
    Cascio A, Colomba C, Antinori S, Orobello M, Paterson D, Titone L (2002) Pediatric visceral leishmaniasis in Western Sicily, Italy: a retrospective analysis of 111 cases. Eur J Clin Microbiol Infect Dis 21(4):277–282PubMedCrossRefGoogle Scholar
  15. 15.
    Pasquau F, Ena J, Sanchez R, Cuadrado JM, Amador C, Flores J, Benito C, Redondo C, Lacruz J, Abril V, Onofre J (2005) Leishmania HIV Mediterreanean Co-operative Group. Leishmaniasis as an opportunistic infection in HIV-infected patients: determinants of relapse and mortality in a collaborative study of 228 episodes in a Mediterreanean region. Eur J Clin Microbiol Infect Dis 24(6):411–418PubMedCrossRefGoogle Scholar
  16. 16.
    Leishmania/HIV co-infection, south-western Europe, 1990–1998 (1999) Wkly Epidemiol Rec 74:365–375Google Scholar
  17. 17.
    Mansueto S, Vitale G, Miceli MD, Montaperto B, Alberti L, Quartararo P (1982) Valutazione di quattro tests (latex-agglutinazione, controimmunoelettroforesi, emoagglutinazione indiretta ed ELISA) nella diagnostica della Leishmaniosi umana. Acta Medit Patol Inf Trop 1(S):75–85Google Scholar
  18. 18.
    Mansueto S, Vitale G, Mocciaro C, Librizzi R, Friscia I, Usticano V, Gambino G, Reina G (1989) Laboratory diagnosis of boutonneuse fever by enzyme-linked immunosorbent assay. Trans R Soc Trop Med Hyg 83(6):855–857PubMedCrossRefGoogle Scholar
  19. 19.
    Alvar J, Aparicio P, Aseffa A, Den Boer M, Cañavate C, Dedet JP, Gradoni L, Ter Horst R, López-Vélez R, Moreno J (2008) The relationship between leishmaniasis and AIDS: the second 10 years. Clin Microbiol Rev 21(2):334–359PubMedCrossRefGoogle Scholar
  20. 20.
    Bern C, Jha SN, Joshi AB, Thakur GD, Bista MB (2000) Use of the recombinant K39 dipstick test and the direct agglutination test in a setting endemic for visceral leishmaniasis in Nepal. Am J Trop Med Hyg 63(3–4):153–157PubMedGoogle Scholar
  21. 21.
    Kaul P, Malla N, Kaur S, Mahajan RC, Ganguly NK (2000) Evaluation of a 200-kDa amastigote-specific antigen of L. donovani by enzyme-linked immunosorbent (ELISA) for the diagnosis of visceral leishmaniasis. Trans R Soc Trop Med Hyg 94(2):173–175PubMedCrossRefGoogle Scholar
  22. 22.
    Singh S, Gilman-Sachs A, Chang KP, Reed SG (1995) Diagnostic and prognostic value of K39 recombinant antigen in Indian leishmaniasis. J Parasitol 81(6):1000–1003PubMedCrossRefGoogle Scholar
  23. 23.
    Singh S, Kumari V, Singh N (2002) Predicting kala-azar disease manifestation in asymptomatic patients with latent Leishmania donovani infection by detection of antibody against recombinant k39 antigen. Clin Diagn Lab Immunol 9(3):568–572PubMedGoogle Scholar
  24. 24.
    Singh S, Sivakumar R (2003) Recent advances in the diagnosis of leishmaniasis. J Postgrad Med 49(1):55–66PubMedCrossRefGoogle Scholar
  25. 25.
    Sundar S, Rai M (2002) Laboratory diagnosis of visceral leishmaniasis. Clin Diagn Lab Immunol 9(5):951–958PubMedGoogle Scholar
  26. 26.
    Houghton RL, Petrescu M, Benson DR, Skeiky YA, Scalone A, Badaró R, Reed SG, Gradoni L (1998) A cloned antigen (recombinant K39) of Leishmania chagasi diagnostic for visceral leishmaniasis in human immunodeficiency virus type 1 patients and a prognostic indicator for monitoring patients undergoing drug therapy. J Infect Dis 177(5):1339–1344PubMedCrossRefGoogle Scholar
  27. 27.
    Cleveland WS (1993) Visualizing data. At & T Bell Laboratories, Murray HillGoogle Scholar

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  • Pasquale Mansueto
    • 1
    Email author
  • Ilenia Pepe
    • 1
  • Aurelio Seidita
    • 1
  • Francesca Scozzari
    • 1
  • Giustina Vitale
    • 1
  • Francesco Arcoleo
    • 2
  • Inglese Elvira
    • 2
  • Enrico Cillari
    • 2
  • Giovam Battista Rini
    • 1
  • Nicola Napoli
    • 3
  • Salvatore Di Rosa
    • 4
  • Serafino Mansueto
    • 1
  • Gaetana Di Fede
    • 5
  1. 1.Dipartimento di Medicina Clinica e delle Patologie EmergentiUniversity of PalermoPalermoItaly
  2. 2.Unità Operativa Complessa di Patologia Clinica, Azienda Ospedaliera Ospedali Riuniti ‘Villa Sofia-Cervello’PalermoItaly
  3. 3.Washington UniversitySt. LouisUSA
  4. 4.Azienda Ospedaliera Ospedali Riuniti ‘Villa Sofia-Cervello’PalermoItaly
  5. 5.Dipartimento di Discipline Chirurgiche ed OncologicheUniversity of PalermoPalermoItaly

Personalised recommendations